A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 52f19f353ed30a6d7a5f8dbda8b40cb93c5d6c29
First added on: Feb 10, 2025